CBD vape in Switzerland — legal framework 2026

TL;DR

• CBD vape products with <1 % THC are in principle marketable.
• Since 1 Oct 2024, the Tobacco Products Act (TobPA) also applies to e-cigarettes & refill liquids.
• Sale to under-18s is prohibited. Advertising restrictions match tobacco.
• Therapeutic claims are prohibited (TPA) — CBD vape is not a medicinal product.

Concrete rules

• THC limit: strictly <1 % in the finished product (NarcO-EDI).
• Nicotine: allowed up to 20 mg/mL (TobPA ordinance).
• Labelling: ingredients, nicotine content, warning, batch number.
• Import: only with TobPA notification to FOPH.
• Public vaping: subject to cantonal passive-smoke protection.

Legal framework for CBD liquids: two regulatory frameworks simultaneously

CBD liquids are subject to dual regulation in Switzerland. Under narcotics law, the total THC value alone is decisive: under 1 % is not a narcotic, above that is. Under product law, the Tobacco Products Act, which has been in force since October 2024, also applies, regulating declaration, a minimum age of 18 for sales, and advertising restrictions. Both levels apply independently of each other — a liquid can be flawless under narcotics law and yet be deficiently declared under product law.

Health claims are not permitted. If a CBD liquid is advertised with a therapeutic effect, it is considered a medicinal product and requires authorization from Swissmedic. Reputable Swiss providers therefore formulate their claims with deliberate restraint — conspicuously strong efficacy promises are an indication of a provider who also does not work carefully when it comes to analysis.

• Total THC of the final product under 1 %, verified by batch analysis
• Complete list of ingredients including carrier substance and flavorings
• Sale only to persons aged 18 and over (TabPG)
• No health claims without Swissmedic authorization

Travel and border crossing

The Swiss 1 % threshold is high by European standards: in most EU countries, the limit is 0.2 or 0.3 % THC. A CBD liquid legally purchased in Switzerland can therefore be considered illegal in neighboring countries, regardless of the Swiss proof of purchase. For travel abroad, the simple rule applies: leave CBD products at home and, if in doubt, check the regulations of the destination country in advance.

In Switzerland, the following applies: cannabis products with less than 1 % total THC (THC + THCA × 0.877) are not narcotics and are freely available. Liquids and vaporizers also fall under the Tobacco Products Act (TabPG) — sales to minors under 18 are prohibited, and advertising is restricted. The analyzed value of the final product is always decisive, not the information on the packaging.

Road traffic and fitness to drive with CBD vaping

Anyone in Switzerland who consumes CBD vapes and actively participates in road traffic must observe the strict legal limits. In Swiss road traffic, a strict zero-tolerance policy applies regarding THC, which is set at a detection limit of 1.5 micrograms of THC per litre of blood. Although CBD products may legally contain less than 1 per cent THC, regular or intensive consumption of CBD liquids can lead to this extremely low limit in the blood being exceeded. During a check, the police do not primarily distinguish between the consumption of legal CBD and illegal cannabis, as the rapid test will yield a positive result.

In the event of a positive preliminary test, a blood analysis is ordered to determine the exact THC level. If this is above the legal detection limit, the person concerned is deemed unfit to drive, which results in the revocation of their driving licence and criminal consequences. Consumers should be aware that even certified Swiss CBD liquids contain minimal traces of THC, which can accumulate in the body. To avoid taking any risks, it is recommended to refrain from driving vehicles after vaping CBD products or to use products with verifiably absolutely no THC content.

• Strict zero-tolerance policy with a limit of 1.5 micrograms of THC per litre of blood in road traffic.
• Accumulation of THC traces in the body is possible through regular consumption of legal CBD vapes.
• Unfitness to drive and revocation of the driving licence if the legal detection limit is exceeded.
• Police saliva tests react to THC residues and require subsequent blood analyses for clarification.

Quality standards and ingredients in the Swiss market

The safety of CBD liquids depends significantly on the carrier substances used and the purity of the extracts. In Switzerland, manufacturers must ensure as part of their self-control obligations that their products do not contain any substances hazardous to health, such as vitamin E acetate, which has caused severe lung damage abroad in the past. Propylene glycol and vegetable glycerin, which are also used in conventional e-cigarettes, are typically used as carrier substances. When purchasing, consumers should ensure that the products are transparently labeled and have been tested by Swiss laboratories for harmful substances, pesticides, and heavy metals.

Synthetic cannabinoids, which are artificially produced and often have unpredictable effects, pose a major risk. Such substances are illegal in Switzerland and fall under the Narcotics Act, as they can cause severe damage to health. In case of suspected poisoning or undesirable side effects from contaminated vapes, Tox Info Suisse provides round-the-clock medical advice via the emergency number 145. Reputable Swiss providers supply certificates of analysis that seamlessly prove the purity of the CBD distillate and the exact cannabinoid content.

• Ban on dangerous additives such as vitamin E acetate in Swiss e-liquids.
• Use of standardized carrier substances such as propylene glycol (PG) and vegetable glycerin (VG).
• Danger from illegal synthetic cannabinoids that do not correspond to natural cannabis.
• Emergency medical advice in case of symptoms of poisoning via Tox Info Suisse on the telephone number 145.

Cantonal enforcement practice and public consumption

Although federal law sets the framework for CBD vapes, the concrete enforcement of youth protection and non-smoker protection regulations lies with the cantons. In practice, this leads to inconsistent handling in Switzerland, particularly regarding vaping in public. Many cantons have equated the vaping of e-cigarettes and CBD vapes with traditional smoking and prohibit consumption in publicly accessible indoor spaces, railway stations, or government buildings. Consumers must therefore inform themselves in advance about the local regulations of the respective canton to avoid fines.

During police checks in public spaces, confusion can also occur, as CBD liquids can hardly be distinguished from THC-rich products by sight or smell. If adults accidentally carry products with a total THC content of over 1 percent that were declared as CBD, they face a fixed penalty fine of 100 francs for quantities of 10 grams or more. The authorities can seize suspicious vapes and have them analyzed in a laboratory. If an illegal THC content is confirmed, the consumer bears the costs of the analysis as well as the legal consequences.

• Cantonal differences in non-smoker protection regulate vaping in public indoor spaces.
• Seizure and laboratory analysis of vapes by the police in cases of reasonable suspicion of illegal THC content.
• Fixed penalty fine of 100 francs for adults in possession of more than 10 grams of illegal THC cannabis.
• Transfer of laboratory analysis costs to the consumer in the event of a positive result above the limit value.

Obligations for manufacturers and importers under the TabPG

With the entry into force of the Tobacco Products Act in October 2024, the obligations for Swiss manufacturers and importers of CBD vapes were drastically tightened. Every new CBD liquid and every vaporizer device must be reported to the Federal Office of Public Health (BAG) before sales begin. This reporting obligation includes detailed information on the ingredients, emissions, and toxicological data of the product. Self-control also obliges market players to only offer products that comply with strict Swiss safety standards and do not feature misleading packaging.

The packaging of CBD vapes must contain clear warning notices warning of the risks of consumption, especially if nicotine is added. In addition, stating the exact total THC content as well as the CBD content is mandatory to comply with protection against deception. Since health claims are strictly prohibited under the Therapeutic Products Act, packaging must not contain any medical promises or representations suggesting a therapeutic effect. Violations of these labeling and reporting obligations are strictly sanctioned by the cantonal laboratories and can lead to a sales ban.

• Mandatory reporting obligation for all CBD liquids and vape devices to the Federal Office of Public Health (BAG).
• Obligation for detailed disclosure of all ingredients and toxicological data.
• Strict labeling requirement with warning notices and a ban on any medical health claims.
• Market monitoring and enforcement of sales bans by cantonal laboratories.

FAQ